Key points in managing MDA5+ DM 1. Monitor lungs - HRCT/PFTs 2. Test muscle endurance (ref: IMACS site) not just strength 3. Close observation 4. MTX/MMF initial treatments 5. Repeat muscle biopsy if diagnosis unclear Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2

Key points in managing MDA5+ DM 1. Consider Tofacitinib 5-10mg bd 2. Low to mid dose Prednisolone 20-30mg tapering 3. Other Rx: Tacrolimus, IVIG 4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw

Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA. Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU

Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0

“The Stone Age did not end because of a shortage of stones. We need new solutions to our problems” Abraham Verghese. Amazing insight into our challenges in clinic today at the #ACR22 opening session @RheumNow

GCA Fast Track clinics are nice - but usually need specialized ultrasound. What if you don't have it? (also, COVID?) @PennRheum implemented *without* ultrasound Excellent outcomes The early referral triage makes all the difference. Knowledge is power ABST0463 #ACR22 @RheumNow https://t.co/rjkVERW559

More details at https://t.co/4U8v7oeUYW Enormously powerful in these times of rheumatology workforce shortage. I would love to see this in Australia and elsewhere - so much to learn. Congratulations to all involved, and thanks @ACRheum and @UCSF for supporting #ACR22

• RAE | Rheumatology Access Expansion

Just published! QR code attached! #ACR22 @RheumNow https://t.co/lMD0mFoT4M

“Rheumatic diseases - diseases of accelerated aging” With age: ⚖️ fat ⬆️ 💪🏻 muscle ⬇️ 👉 results in ⬇️fn ⬇️gait speed ⬇️grip 🌟what can we do? ⚡️start with basic diet and exercise advice ✅caloric restriction (⬇️350cal/day) ✅ resistance training #GeriRheum #ACR22 https://t.co/6KRrwCWBEZ

Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

England et al. Influence of FVC on choice of b/tsDMARD in RA-ILD. FVC predicts hospitalisation and mortality. However, it did not appear to influence choice of b/tsDMARD. Overall 67% of RA-ILD patients initiated TNFi, weird! @rheumnow #ACR22 Abstr#245 https://t.co/swuNHv96WD https://t.co/vy5FUPnNjo

• Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcom…

Interesting observation: Late-onset PsA assoc'd w/ male sex, greater structural damage, higher frequency of arthritis, and greater loss of functionality (BASFI). Interestingly, shorter time of symptom duration to dx. Abs 0377 #ACR22 @RheumNow https://t.co/m15c37FltD https://t.co/3LRy4Ltde6

• Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RE…

#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow

Difficult to treat #rheumatoidarthritis - phenotypes need to be defined and order of Rx may be v Impt. Well, it is really difficult @RheumNow #ACR22 session 12S127 https://t.co/x3bkUP590A

So does PsA affect your capacity to work? DISCOVER-2 analysis: It’s presenteeism, not absenteeism which is the issue PsA pts drag themselves into work, but treating them helps them actually do their job. We need to fund more rheumatologists! ABST0509 @RADoctor #ACR22 @RheumNow https://t.co/Jnac6mV9O5